Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Development of New Psychopharmacological Agents for Depression and Anxiety PSYCHIATRIC CLINICS OF NORTH AMERICA Schatzberg, A. F. 2015; 38 (3): 379-?

Abstract

Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures. Lastly, possible solutions for improving the likelihood of the success of antidepressant/anxiolytic agents are discussed.

View details for DOI 10.1016/j.psc.2015.05.009

View details for Web of Science ID 000361501200003

View details for PubMedID 26300029